Comparative Pharmacology
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus PURIXAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUDARABINE PHOSPHATE versus PURIXAN.
FLUDARABINE PHOSPHATE vs PURIXAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fludarabine phosphate is a purine analog that inhibits DNA synthesis by interfering with ribonucleotide reductase and DNA polymerase, leading to apoptosis in lymphocytes.
Purixan (mercaptopurine) is a purine analog that inhibits de novo purine synthesis by interfering with nucleotide interconversion and incorporation into DNA and RNA. It requires intracellular activation to 6-mercaptopurine ribonucleotide (6-MP ribonucleotide) via hypoxanthine-guanine phosphoribosyltransferase (HGPRT).
25 mg/m2 intravenously over 30 minutes daily for 5 consecutive days every 28 days.
75 mg/kg once weekly orally; may be increased by 25 mg/kg every 2-4 weeks to a maximum of 150 mg/kg once weekly.
None Documented
None Documented
Terminal half-life of 2-fluoro-ara-A is approximately 20 hours (range 10–30 hours). Clinical context: accumulation occurs with repeated dosing, requiring dose adjustment in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment. Clinically, monitoring for myelosuppression is essential due to accumulation.
Renal excretion of the active metabolite 2-fluoro-ara-A accounts for approximately 60% of drug elimination. Biliary/fecal elimination is minimal (<5%).
Renal excretion of unchanged drug and metabolites; approximately 50% as unchanged drug, 20% as 6-thiouric acid, and minor amounts as other metabolites. Biliary/fecal elimination accounts for less than 10%.
Category D/X
Category C
Antimetabolite
Antimetabolite